| Literature DB >> 34422039 |
Sepide Namdari1,2, Ali Farhadi1, Aida Khademalhoseini1, Abbas Behzad-Behbahani1, Afsaneh Moaddeb3.
Abstract
BACKGROUND: The emergence of multidrug-resistant (MDR) microorganisms causing infections is increasing worldwide and becoming more serious in developing countries. Among those, Acinetobacter species are becoming prominent.Entities:
Year: 2021 PMID: 34422039 PMCID: PMC8378981 DOI: 10.1155/2021/5265379
Source DB: PubMed Journal: Interdiscip Perspect Infect Dis ISSN: 1687-708X
Distribution of bacteria isolated from different samples collected from patients with infections.
| Microorganism | Source of specimen | |||||
|---|---|---|---|---|---|---|
| Total | Urine | Blood | Wound | Sputum | ETT | |
| Number of isolates (%) | ||||||
| 185 (10.4) | 0 | 9 (6.9) | 19 (8.0) | 82 (28.2) | 75 (44.9) | |
| 62 (3.5) | 44 (4.6) | 6 (4.6) | 12 (5.0) | 0 | 0 | |
| 117 (6.6) | 77 (8.1) | 12 (9.2) | 28 (11.8) | 0 | 0 | |
|
| 659 (37.1) | 590 (62.0) | 21 (16.1) | 15 (6.3) | 22 (7.6) | 11 (6.6) |
| 248 (13.9) | 154 (16.2) | 13 (10.0) | 27 (11.3) | 34 (11.7) | 20 (12.0) | |
| 63 (3.5) | 41 (4.3) | 5 (3.8) | 17 (7.1) | 0 | 0 | |
|
| 142 (8.0) | 29 (3.0) | 8 (6.1) | 39 (16.4) | 35 (12.0) | 31 (18.6) |
|
| 134 (7.5) | 17 (1.8) | 12 (9.2) | 52 (21.8) | 34 (11.7) | 19 (11.4) |
|
| 77 (4.3) | 0 | 26 (20.0) | 29 (12.2) | 11 (3.8) | 11 (6.6) |
|
| 24 (1.3) | 0 | 11 (8.5) | 0 | 13 (4.5) | 0 |
|
| 49 (2.7) | 0 | 0 | 0 | 49 (16.8) | 0 |
| Other nonfermentative bacteria | 18 (1.0) | 0 | 7 (5.4) | 0 | 11 (3.8) | 0 |
| Total | 1778 | 952 | 130 | 238 | 291 | 167 |
ETT: endotracheal tube specimen.
Distribution of bacteria isolated from patients with infections in different hospital wards.
| Microorganism | Hospital ward | ||||||
|---|---|---|---|---|---|---|---|
| Internal medicine | Surgical wards | Pediatric ward | NICU | ICU | CCU | Emergency department | |
| Number of isolates (%) | |||||||
| 25 (4.9) | 29 (7.1) | 19 (8.2) | 32 (15.0) | 59 (28.9) | 18 (13.6) | 3 (4.0) | |
| 18 (3.5) | 16 (3.9) | 5 (2.2) | 2 (0.9) | 6 (2.9) | 12 (9.1) | 3 (4.0) | |
| 10 (1.9) | 38 (9.3) | 7 (3.0) | 13 (6.1) | 25 (12.2) | 18 (13.6) | 6 (8.0) | |
|
| 265 (51.6) | 168 (41.1) | 105 (45.4) | 49 (23.0) | 30 (14.7) | 13 (9.8) | 29 (38.7) |
| 94 (18.3) | 22 (5.4) | 35 (15.1) | 38 (17.8) | 15 (7.3) | 26 (19.7) | 18 (24) | |
| 19 (3.7) | 18 (4.4) | 4 (1.7) | 7 (3.3) | 5 (2.4) | 6 (4.5) | 4 (5.3) | |
|
| 19 (3.7) | 26 (6.4) | 15 (6.5) | 34 (15.9) | 27 (13.2) | 19 (14.4) | 2 (2.7) |
|
| 34 (6.6) | 62 (15.2) | 6 (2.6) | 13 (6.1) | 9 (4.4) | 8 (6.1) | 2 (2.7) |
|
| 14 (2.7) | 16 (3.9) | 12 (5.2) | 8 (3.7) | 18 (8.8) | 6 (4.5) | 3 (4.0) |
|
| 3 (0.6) | 7 (1.7) | 5 (2.2) | 3 (1.4) | 3 (1.5) | 2 (1.5) | 1 (1.3) |
|
| 9 (1.7) | 0 | 17 (7.4) | 12 (5.6) | 5 (2.4) | 3 (2.3) | 3 (4.0) |
| Other nonfermentative bacteria | 4 (0.8) | 7 (1.7) | 1 (0.4) | 2 (0.9) | 2 (1.0) | 1 (0.8) | 1 (1.3) |
| Total | 514 | 409 | 231 | 213 | 204 | 132 | 75 |
Figure 1Frequency of bacteria isolated from clinical samples of patients with infections; NFB: nonfermentative bacteria.
Prevalence of bacterial infections during the three-year study period.
| Microorganism | Sample collection dates | ||
|---|---|---|---|
| 2016-2017 | 2017-2018 | 2018-2019 | |
| Number of isolates (%) | |||
| 39 (7.2) | 58(10.0) | 88 (13.3) | |
| 17 (3.1) | 23 (4.0) | 22 (3.3) | |
| 43 (8.0) | 39 (6.7) | 35 (5.3) | |
|
| 188 (34.9) | 217 (37.3) | 254 (38.5) |
| 69 (12.8) | 83 (14.3) | 96 (14.6) | |
| 27 (5.0) | 22 (3.8) | 14 (2.1) | |
|
| 66 (12.2) | 44 (7.6) | 32 (4.8) |
|
| 45 (8.4) | 44 (7.6) | 45 (6.8) |
|
| 23 (4.3) | 19 (3.3) | 35 (5.3) |
|
| 5 (0.9) | 10 (1.7) | 9 (1.4) |
|
| 12 (2.2) | 15 (2.6) | 22 (3.3) |
| Other nonfermentative bacteria | 4 (0.7) | 7 (1.2) | 7 (1.1) |
| Total | 538 | 581 | 659 |
Antibiotic resistance patterns of Gram-positive bacteria isolated from patients with infections.
| Antibiotics |
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R% | I% | S% | R% | I% | S% | R% | I% | S% | R% | I% | S% | |
| Amikacin | NA | NA | NA | 3.0 | 0 | 97.0 | 7.8 | 3.9 | 88.3 | NA | NA | NA |
| Ciprofloxacin | 93.2 | 5.1 | 1.7 | 22.4 | 4.5 | 73.1 | 63.6 | 1.3 | 35.1 | NA | NA | NA |
| Nitrofurantoin | 11.1 | 21.4 | 67.5 | 20.1 | 7.5 | 72.4 | 3.9 | 3.9 | 92.2 | NA | NA | NA |
| Gentamicin | 84.6 | 8.5 | 6.8 | 14.2 | 0 | 85.8 | 28.6 | 5.2 | 66.2 | NA | NA | NA |
| Ceftriaxone | NA | NA | NA | 30.6 | 5.2 | 64.2 | 71.4 | 11.7 | 16.9 | 42.9 | 4.1 | 53.1 |
| SXT | NA | NA | NA | 20.1 | 3.0 | 76.9 | 58.4 | 1.3 | 40.2 | 32.6 | 4.1 | 63.3 |
| Norfloxacin | 94 | 4.3 | 1.7 | 39.6 | 6.7 | 53.7 | 63.6 | 1.3 | 35.1 | NA | NA | NA |
| Tetracycline | 92.3 | 0 | 7.7 | 42.5 | 0.7 | 56.7 | 64.9 | 0 | 35.1 | 51.0 | 6.1 | 42.9 |
| Vancomycin | 75.2 | 17.9 | 6.8 | 0 | 0 | 100 | 1.3 | 0 | 98.7 | 0 | 0 | 100 |
| Ampicillin | 60.7 | 4.3 | 35.0 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Chloramphenicol | 32.5 | 13.7 | 53.8 | 8.2 | 6.0 | 85.8 | 5.2 | 3.9 | 90.9 | 12.2 | 0 | 87.7 |
| Clindamycin | NA | NA | NA | 33.6 | 4.5 | 61.9 | 71.4 | 2.6 | 26.0 | 28.6 | 2.0 | 69.4 |
| Erythromycin | NA | NA | NA | 38.8 | 5.2 | 56.0 | 84.4 | 0 | 15.6 | 30.6 | 6.1 | 63.2 |
R: resistant, I: intermediate, S: sensitive, SXT: Co-Trimoxazole, and NA: not applicable.
Antibiotic resistance patterns of Gram-negative bacteria isolated from patients with infections.
| Antibiotics |
|
|
| Other NFB |
| |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R% | I% | S% | R% | I% | S% | R% | I% | S% | R% | I% | S% | R% | I% | S% | R% | I% | S% | R% | I% | S% | R% | I% | S% | |
| Ceftizoxime | 53.6 | 8.6 | 37.8 | 52.0 | 2.8 | 45.2 | 37.1 | 6.4 | 56.4 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 11.1 | 1.6 | 87.3 |
| Amikacin | 5.3 | 5 | 89.6 | 22.6 | 2.4 | 75.0 | 8.0 | 6.4 | 85.5 | 9.9 | 1.4 | 88.7 | 95.7 | 2.7 | 1.6 | 8.3 | 0 | 91.7 | 44.4 | 0 | 55.6 | 0 | 0 | 100 |
| Cefixime | 63.7 | 1.4 | 34.9 | 54.4 | 2.0 | 43.5 | 48.4 | 4.8 | 46.8 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 12.7 | 4.8 | 82.5 |
| Ciprofloxacin | 54.9 | 6.4 | 38.7 | 30.6 | 6.8 | 62.5 | 14.5 | 4.8 | 80.6 | 15.5 | 0 | 84.5 | 98.9 | 0.5 | 0.5 | 4.2 | 0 | 95.8 | 11.1 | 22.2 | 66.7 | 28.6 | 6.3 | 65.1 |
| Nitrofurantoin | 18.7 | 12.0 | 69.2 | 68.5 | 23.0 | 8.5 | 69.3 | 6.4 | 24.2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Gentamicin | 27.0 | 0.9 | 72.1 | 28.2 | 0.4 | 71.3 | 21.0 | 0 | 79.0 | 9.9 | 0.7 | 89.4 | 94.6 | 1.1 | 4.3 | 8.3 | 0 | 91.7 | 44.4 | 0 | 55.6 | 6.3 | 0 | 93.6 |
| Nalidixic acid | 69.8 | 2.7 | 27.5 | 35.1 | 10.1 | 54.8 | 35.5 | 8.0 | 56.4 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 52.4 | 0 | 47.6 |
| Ceftriaxone | 64.0 | 0.9 | 35 | 37.1 | 5.6 | 57.3 | 32.3 | 6.4 | 61.3 | NA | NA | NA | 69.7 | 1.6 | 28.6 | NA | NA | NA | NA | NA | NA | 7.9 | 11.1 | 80.9 |
| SXT | 66.2 | 0.3 | 33.5 | 47.2 | 4.0 | 48.8 | 30.6 | 3.2 | 66.1 | NA | NA | NA | 96.8 | 1.6 | 1.6 | 8.3 | 0 | 91.7 | 27.8 | 0 | 72.2 | 65.1 | 0 | 34.9 |
| Norfloxacin | 56.8 | 3.2 | 40 | 27.8 | 1.2 | 71.0 | 21.0 | 0 | 79.0 | 27.5 | 0 | 72.5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 23.8 | 0 | 76.2 |
| Tetracycline | 63.7 | 0.6 | 35.7 | 38.3 | 12.1 | 49.6 | 33.9 | 9.7 | 56.4 | NA | NA | NA | 73.0 | 3.2 | 23.8 | 16.7 | 0 | 83.3 | 55.6 | 5.6 | 38.9 | NA | NA | NA |
| Chloramphenicol | 24.7 | 8.6 | 66.6 | 32.7 | 4.0 | 63.3 | 24.2 | 9.7 | 66.1 | NA | NA | NA | NA | NA | NA | 0 | 8.3 | 91.7 | 61.1 | 22.2 | 16.7 | 41.3 | 17.5 | 41.3 |
| Imipenem | 41.0 | 20.0 | 39.0 | 40.3 | 16.9 | 42.7 | 25.8 | 8.0 | 66.1 | 15.5 | 9.1 | 75.3 | 99.5 | 0 | 0.5 | 66.7 | 8.3 | 25.0 | 50.0 | 16.7 | 33.3 | NA | NA | NA |
| Colistin | 6.8 | 0 | 93.2 | 1.2 | 0 | 98.8 | 6.4 | 0 | 93.5 | 0 | 0 | 100 | 0 | 0 | 100 | 12.5 | 0 | 87.5 | 44.4 | 0 | 55.6 | NA | NA | NA |
R: resistant, I: intermediate, S: sensitive, SXT: Co-Trimoxazole, NFB: nonfermentative bacteria, and NA: not applicable.
Multidrug resistance patterns of Gram-positive bacteria isolated from patients with infections.
| Microorganism | Number of antibiotics | Antibiotic resistant isolates | Multidrug resistance patterns |
|---|---|---|---|
| 5 | 48 (41.0) | CIP, TE, GM, V, AMP | |
| 4 | 26 (22.2) | CIP, TE, GM, V | |
| 4 | 19 (16.2) | CIP, TE, GM, AMP | |
| 3 | 6 (5.1) | CIP, TE, GM | |
| 3 | 8 (6.8) | CIP, TE, V | |
|
| |||
| 5 | 3 (2.2) | CIP, GM, E, CC, SXT | |
| 4 | 10 (7.5) | CIP, E, CC, TE | |
| 3 | 6 (4.5) | E, SXT, CHL | |
| 3 | 3 (2.2) | GM, E, CHL | |
| 3 | 13 (9.7) | E, CC, TE | |
| 3 | 8 (6.0) | CIP, E, CC | |
| 3 | 9 (6.7) | CIP, GM, E | |
|
| |||
| 5 | 5 (6.5) | CIP, GM, E, CC, SXT | |
| 4 | 6 (7.8) | E, CC, TE, SXT | |
| 4 | 5 (6.5) | CIP, E, CC, TE | |
| 3 | 2 (2.6) | GM, E, CHL | |
| 3 | 8 (10.4) | E, CC, TE | |
| 3 | 11 (14.3) | CIP, E, CC | |
| 3 | 13 (16.9) | E, TE, SXT | |
|
| |||
| 4 | 3 (6.1) | E, CC, TE, SXT | |
| 3 | 5 (10.2) | E, CC, TE | |
CIP: Ciprofloxacin, TE: Tetracycline, GM: Gentamicin, V: Vancomycin, AMP: Ampicillin, E: Erythromycin, CC: Clindamycin, SXT: Co-Trimoxazole, and CHL: Chloramphenicol.
Multidrug resistance patterns of Gram-negative bacteria isolated from patients with infections.
| Microorganism | Number of antibiotics | Antibiotic resistant isolates | Multidrug resistance patterns |
|---|---|---|---|
| 6 | 45 (6.8) | SXT, TE, IMP, GM, CHL, COL | |
| 5 | 35 (5.3) | SXT, CRO, CIP, GM, AMK | |
| 4 | 58 (8.8) | SXT, TE, CIP, GM | |
| 4 | 36 (5.5) | SXT, TE, CHL, CIP | |
| 3 | 62 (9.4) | SXT, TE, CHL | |
| 3 | 66 (10) | SXT, TE, IMP | |
| 3 | 54 (8.2) | SXT, CRO, CIP | |
|
| |||
| 5 | 3 (1.2) | SXT. TE, CIP, GM, COL | |
| 4 | 47 (18.9) | CRO, CIP, GM, AMK | |
| 3 | 33 (13.3) | SXT, TE, IMP | |
| 3 | 36 (14.5) | SXT, TE, CHL | |
| 3 | 26 (10.5) | SXT, CRO, CIP | |
|
| |||
| 4 | 4 (6.4) | CRO, CIP, GM, AMK | |
| 3 | 6 (9.7) | SXT, TE, CRO | |
| 3 | 7 (11.3) | SXT, TE, IMP | |
| 3 | 6 (9.7) | SXT, TE, CHL | |
|
| |||
| 4 | 14 (9.9) | IMP, CIP, GM, AMK | |
|
| |||
| 7 | 129 (69.7) | SXT, TE, IMP, CRO, CIP, GM, AMK | |
| 6 | 6 (3.2) | SXT, TE, IMP, CIP, GM, AMK | |
| 5 | 31 (16.7) | SXT, IMP, CIP, GM, AMK | |
| 4 | 6 (3.2) | IMP, CIP, GM, AMK | |
| 4 | 2 (1.1) | SXT, IMP, GM, AMK | |
| 4 | 1 (0.5) | SXT, CIP, GM, AMK | |
| 4 | 2 (1.1) | SXT, IMP, CIP, AMK | |
| 3 | 8 (4.3) | SXT, IMP, CIP | |
|
| |||
| 3 | 5 (7.9) | SXT, CHL, CIP | |
SXT: Co-Trimoxazole, TE: Tetracycline, IMP: Imipenem, GM: Gentamicin, CHL: Chloramphenicol, COL: Colistin, CRO: Ceftriaxone, CIP: Ciprofloxacin, and AMK: Amikacin.